Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b open-label study of subcutaneous amivantamab combinations in EGFR-mutated advanced or metastatic non-small cell lung cancer
MOH_2025-08-31_014305Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of amivantamab and lazertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Janssen Pharmaceutical. Started Aug 2025; status: recruiting.
02
Drugs
amivantamablazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2025-08-31_014305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-08-31_014305.